Inclusion Criteria:  Newly diagnosed exocrine pancreatic cancer with pathology confirmed as adenocarcinoma Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines ≥ 18 years old at the time of informed consent ECOG Performance Status 0, or 1 Patients who are candidates for standard of care (SOC) neoadjuvant chemotherapy. Patients may be enrolled in a clinical trial. Ability to provide written informed consent and HIPAA authorization Patient must agree on blood collection at assigned time points for biomarker analysis Patients must have a life expectancy of at least 6 months  Exclusion Criteria:  Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies Positive pregnancy test, pregnant, or breastfeeding Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study